

**Guide to the March Quarterly Update of the
Fiscal Year 2023
Dialysis Facility Report (DFR):
*Overview, Methodology, and Interpretation***

March 2023

**Guide to the Quarterly Updates of the FY 2023 Dialysis Facility Reports:
Overview, Methodology, and Interpretation**

Table of Contents

| | |
|---|----|
| I. PURPOSE OF THIS GUIDE AND THE QUARTERLY UPDATES OF THE DIALYSIS FACILITY REPORTS | 1 |
| <i>What's New in the QDFR this Quarter</i> | 1 |
| II. OVERVIEW | 1 |
| III. ASSIGNING PATIENTS TO FACILITIES | 3 |
| IV. ELIGIBLE PATIENTS | 4 |
| <i>Eligible Adult Patients</i> | 4 |
| <i>Eligible Adult Hemodialysis and Peritoneal Patients</i> | 4 |
| V. INFECTION/DIALYSIS ACCESS..... | 4 |
| <i>Long-Term Catheter Rate</i> | 5 |
| <i>Adult HD Patients with Arteriovenous (AV) Fistulae in Use</i> | 5 |
| VI. FLUID MANAGEMENT | 5 |
| <i>Ultrafiltration Rate (UFR) Among Adult HD Patients</i> | 6 |
| VII. ANEMIA | 6 |
| <i>Patients with hemoglobin < 10 g/dL</i> | 6 |
| VIII. DIALYSIS ADEQUACY | 6 |
| <i>Determination of thrice weekly dialysis</i> | 6 |
| <i>Kt/V Categories for Adult HD Patients</i> | 7 |
| <i>Weekly Kt/V Categories for Adult PD Patients</i> | 7 |
| IX. NUTRITION | 8 |
| <i>Serum Albumin Categories Among HD Patients</i> | 8 |
| <i>Serum Albumin Categories Among PD patients</i> | 8 |
| X. INFLUENZA VACCINATION | 9 |
| XI. MINERAL METABOLISM | 9 |
| <i>Phosphorous Categories Among Adult Patients</i> | 9 |
| <i>Calcium Uncorrected Categories Among Adult Patients</i> | 9 |
| <i>Average Uncorrected Calcium > 10.2 mg/dL (1y)</i> | 10 |
| XII. TRANSPLANTATION | 10 |
| <i>Percentage of Patient-months on the Waitlist</i> | 10 |
| XIII. NURSING HOME PATIENTS..... | 11 |
| XIV. COVID TABLES (C1 AND C2) | 11 |
| XVIII. PLEASE GIVE US YOUR COMMENTS | 12 |
| REFERENCES..... | 13 |

I. Purpose of this Guide and the Quarterly Updates of the Dialysis Facility Reports

This guide explains the contents of the Quarterly Updates of the Dialysis Facility Reports prepared for each dialysis facility under contract to the Centers for Medicare & Medicaid Services. Included here are the reports' objectives, discussions of methodological issues relevant to particular sections of each report, and descriptions of each data summary.

In the interest of facilitating the quality improvement effort, the Quarterly Updates of the Dialysis Facility Reports provide more recent data for select measures reported in the FY 2023 DFR available to those involved in provision and quality of dialysis care. This report provides a tool to compare patterns in dialysis access, fluid management, anemia, dialysis adequacy, nutrition, and mineral metabolism to local and national averages. Such comparisons help evaluate patient outcomes, which may enhance each facility's understanding of the clinical experience relative to other facilities in the state, Network, and nation.

What's New in the QDFR this Quarter

The following changes have been incorporated into the December 2022 Quarterly Update of the FY 2023 DFR table:

- All Summaries for 2020 were updated to include EQRS data for the fourth quarter 2020 (Oct-Dec).
- Influenza vaccination summaries are now based on information submitted in EQRS and include non-Medicare patients, and the most recent flu season, August 2021-March 2022 is reported.
- The number of nursing home patients treated at the end of each year/quarter, modality, and standardized mortality and hospitalization ratios among nursing home patients were added to the nursing home section.

Data Limitations

The COVID Extraordinary Circumstances Exception (ECE) data policy from CMS restricts the use of claims data from March-June 2020 and EQRS clinical data from January-June 2020.

II. Overview

The University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) has produced the Quarterly Updates of the Dialysis Facility Reports for FY 2023 with funding from the Centers for Medicare & Medicaid Services (CMS). Each facility's report is distributed to the facility on the secure Dialysis Reports Web site (www.Dialysisdata.org). Those state agencies responsible for certifying dialysis facilities utilize the reports as a resource during the survey and certification process.

Each report provides summary data on each facility's chronic dialysis patients for the years 2020 and 2021 from the FY 2023 DFR along with quarterly summaries for January-August of 2022. Regional and national averages for 2021 are included to allow for comparisons.

Italicized outcomes are updated annually in September. Please refer to the Guide to the FY 2023 Dialysis Facility Reports for details regarding their calculation. Unless otherwise specified, data refer to combined results for hemodialysis (HD) and peritoneal dialysis (PD) patients.

These summaries are compiled using the UM-KECC ESRD patient database, which is largely derived from the CMS End Stage Renal Disease Quality Reporting System (EQRS) End system, which includes the CMS Annual Facility Survey (Form CMS-2744), the CMS Medical Evidence Form (Form CMS-2728), the Medicare Enrollment Database (EDB), and the Death Notification Form (Form CMS-2746); Medicare dialysis and hospital payment records; transplant data from the Organ Procurement and Transplant Network (OPTN), the Nursing Home Minimum Dataset; the Internet Quality Improvement and Evaluation System (iQES), which includes data from the Certification and Survey Provider Enhanced Report System (CASPER); and data from the Dialysis Facility Compare (DFC). The database is comprehensive for Medicare patients. Non-Medicare patients are included in all sources except for the Medicare payment records. EQRS provides tracking by dialysis provider and treatment modality for non-Medicare patients.

This quarterly report is provided for nearly 8,000 Medicare-approved dialysis facilities in the United States that received a FY 2023 DFR and were indicated as active according to iQIES as of 3/01/2022 and/or EQRS as of 9/15/2022. Reports were not created for transplant-only facilities or U.S. Department of Veterans Affairs (VA)--only facilities. We welcome your participation and feedback concerning the clarity, utility, limitations, and accuracy of this report. You will find information on how to directly provide feedback to us at the UM-KECC in Section XIII.

This guide discusses the meaning of the data summaries each report provides, and describes the methodology used to calculate each quarterly summary. For additional information regarding the outcomes updated annually in italic font, please refer to section of the *Guide to the FY 2023 Dialysis Facility Reports* referenced in the footnote for the outcome. Section III describes UM-KECC's patient assignment algorithms used for all (except waitlist) quarterly measures reported. Section IV describes the eligible patient counts from which the eligible patients for the measures in this report are derived. Sections V-XIII are organized according to the order of the summaries in the Quarterly Update of the Dialysis Facility Report, and may serve as references for their interpretation.

The first page provides the purpose and overview of the report, and instructions for submitting questions to UM-KECC and comments for your state surveyor(s). The following page provides quarterly updates of COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2) in 2020 and 2021 Q1-Q3. State, Network, and National averages for 2021 are reported for comparison. The following two pages include a table with quarterly updates from the FY 2023 DFR for the following measure areas for the facility: dialysis access, fluid management, anemia, dialysis adequacy, nutrition, mineral metabolism, and summaries among nursing home patients. Annual mortality, hospitalization, infection, influenza vaccinations, transplant, age-adjusted waitlist

summaries for 2020 and 2021 from the FY 2023 DFR are also reported. For all summaries, annual summaries for 2020 and 2021, and regional averages for 2021 from the FY 2023 DFR are included for comparison. With the exception of the waitlist measure, all quarterly summaries are from EQRS.

Each row of a table in the report summarizes an item. The facility has a column for each time period and three columns for the corresponding geographical summaries, including averages for the facility's state, its ESRD Network, and the entire nation. Whenever the statistic reported was a count (n), we calculated regional and national averages by taking the average count for all facilities in that area. When a statistic was a percent, rate, or ratio, we calculated regional and national summaries by pooling together all individual patients in that area to obtain an estimate for that area as if it were one large facility. We do not report state summary data for dialysis facilities in states or U.S. territories with only one or two dialysis units.

III. Assigning Patients to Facilities

This section describes the methods we used to assign patients to facilities to calculate all measures based on data from EQRS. Additional details regarding patient eligibility for each summary may be found in the section specific to that measure.

An important purpose of this report is to provide and seek feedback on the quality of these data. Much of this report relies on a reasonably accurate and complete description of the patients being treated in each facility at a particular point in time. We believe the overall results warrant a high level of confidence in the assignment of patients to providers. UM-KECC will continue its efforts to measure and improve the quality of all data presented in this report through comparisons with other available data sources.

For each patient, we identified the dialysis provider at each point in time primarily using data from EQRS, the Medical Evidence Form (Form CMS-2728) and Medicare- dialysis claims. Both patient assignment to the provider and modality (either hemodialysis or peritoneal dialysis) were determined according to the information reported in the above mentioned data sources. For each reporting month, patients were required to have been indicated as treated by the facility for the complete month in order to be included in the denominator for these measures. If a patient transferred in or out of the facility, discontinued dialysis, recovered renal function or died anytime during the month, the entire patient-month is excluded. Please note that the number of sessions are not considered and the patient may not have received treatment at the facility for the entire month to be included. For example, if a patient is hospitalized or travels during the month, the patient may still be included in the facility's measure if they are indicated as the facility's patient that month according to the data as described above. Additionally, patients for whom the only evidence of dialysis treatment is the existence of Medicare claims were considered lost to follow-up and removed from a facility's analysis one year following the last claim, if there was no earlier evidence of transfer, recovery, or death. In other words, if a period of one year passed with neither Medicare dialysis claims nor EQRS information to indicate

that a patient was receiving dialysis treatment, we considered the patient lost to follow-up, and did not use him or her in the analysis.

IV. Eligible Patients

This section reports eligible patient counts for the EQRS summaries that are updated quarterly. The counts reported in this section may differ from the eligible patients included in each measure. Any differences from the criteria described below for these counts are noted in the specific section of this Guide related to the measure and is also provided in the footnote for the outcome.

Eligible Adult Patients

The number of adult patients on ESRD more than 90 days who have received dialysis (any modality) at the facility for at least one entire reporting month according to the methods described above in Section III are reported in this row. A patient may only be assigned to one facility each month. Patients may be counted up to 3 or 12 times per quarter or year, respectively. Calcium uncorrected categories reported under the Mineral Metabolism section are based on this count.

Eligible Adult Hemodialysis and Peritoneal Patients

These counts include the number of eligible adult hemodialysis (HD; home or in-center) and peritoneal dialysis (PD) patients on ESRD more than 90 days who have received HD or PD, respectively, at the facility for at least one entire reporting month according to the methods described above in Section III. Patients included in the HD and PD counts may only be assigned to one facility each month and may not switch modalities during the month. Patients may be counted up to 3 or 12 times per quarter or year, respectively.

V. Infection/Dialysis Access

This section of the table reports dialysis access information of all eligible adult HD patients (not excluding patients with ESRD less than 90 days) and is based on information collected in EQRS. Patients with a catheter that had limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. If there was no EQRS vascular access type entry for a given month in the assigned facility, access type reported by other facilities were searched for an access type entry that either indicated catheter or to confirm access type was also missing for the entire month for this exclusion.

The percentage of adult hemodialysis patient-months using an autogenous arteriovenous (AV) fistula as the sole means of vascular access is intended to be jointly reported with Hemodialysis Vascular Access: Long-term Catheter Rate. These two vascular access quality measures, when used together, consider AV fistula use as a positive outcome and prolonged use of a tunneled catheter as a negative outcome. With the growing recognition that some patients have exhausted options for an AV fistula or have comorbidities that may limit the success of AV fistula creation, joint reporting of the measures accounts for all three vascular access options: fistula, graft, and catheter. This paired incentive structure that relies on both measures (AV fistula and long-term catheter rate) reflects consensus

best practice, and supports maintenance of the gains in vascular access success achieved via the Fistula First/Catheter Last Project over the last decade.

Long-Term Catheter Rate

This measure reports the percentage of all eligible adult HD patient-months from Section IV where a long-term catheter was in use, i.e., a catheter was reported for three consecutive months (the reporting month and preceding two months) in the same facility. This row reports the percentage of patient-months in which the patient received dialysis through a catheter for at least three consecutive months (the reporting month and preceding two months) in the same facility. The last vascular access type listed in EQRS during each of these three complete months for the patient was selected to determine whether a catheter was in use. Before indicating that a catheter was present for three consecutive months, we checked that the access type reported on the last day of the month that was three months before the reporting month was also a catheter. A catheter was considered in use if the EQRS “Access Type IDs” of 16, 569, 18, 571, 19, 572, 20, 574, 21, or 573 had been recorded for a given month, where “16” and “569” represent AV Fistula combined with a Catheter, “18” and “571” represent AV Graft combined with a Catheter, “19” and “572” represent Catheter only, “20” and “574” represent Port access only, “21” and “573” represent other/unknown. If the most recent EQRS vascular access type entry for a given month in the assigned facility was missing, access type was set to the last value submitted for the patient from other facilities. If there was no access type from either the assigned facility or all other facilities, vascular access type for that month was counted as a catheter. If a patient changes dialysis facilities, the counting of the three consecutive complete months restarts at the new facility. Summaries for 2018-2021 are reported in Table 11 (row g) of the FY 2023 DFR.

Data limitations for 2020

Due to the lookback period for LTCR, values were calculated only for October through December 2020.

Adult HD Patients with Arteriovenous (AV) Fistulae in Use

The percentage of adult HD patient months from Section IV in which the patient received dialysis through arteriovenous (AV) fistulae (one or two needles). If multiple access types were reported for a month, the most recent non-missing access type was selected. The same process for access type assignment described above for Long Term Catheter Rate is used for fistula access types (EQRS “Access Type IDs” of 14, 567, 22, 605) if there was no EQRS vascular access type entry in the assigned facility. Patients who had an AV graft or a catheter in use with an AV fistula in place for *future* use are included in the AV graft or catheter category, respectively. Port access devices are included in the catheter category. Patients are classified as having missing access types if the vascular access data were not available. Summaries for 2018-2021 are reported in Table 11 (row c) of the FY 2023 DFR.

VI. Fluid Management

This section includes measures of fluid management for hemodialysis (HD) patients and is based on information collected in EQRS.

Ultrafiltration Rate (UFR) Among Adult HD Patients

The ultrafiltration rate (UFR) was assessed among all eligible adult HD patients from Section IV and was characterized into three mutually exclusive categories: missing (no UFR reported), in range (UFR between 0 and 20 ml/kg/hr), and out of range (UFR greater than 20 ml/kg/hr). The percentage of patient-months with in-range values > 13 ml/kg/hr and with missing or out of range values are shown in this row. When multiple values were submitted for the patient (by any facility) during the month, the last value reported was selected. Summaries for 2018-2021 are reported in Table 9 (row g) of the FY 2023 DFR.

VII. Anemia

This section of the table reports hemoglobin separately for hemodialysis (HD) and peritoneal dialysis (PD) patients and is based on information collected in EQRS.

Patients with hemoglobin < 10 g/dL

Hemoglobin values less than 5 or greater than 20 were considered out of range and set to missing. The percentages of all HD and PD patient-months with in-range values with hemoglobin less than 10g/dL among patients reported in Section IV are reported in this section, respectively. Summaries for 2018-2021 are reported in Table 8 (row d for HD, row i for PD) of the FY 2023 DFR.

VIII. Dialysis Adequacy

This section of the table reports measures of dialysis adequacy separately for hemodialysis (HD) and peritoneal dialysis (PD) patients for patients reported in Section IV. Additionally, the HD Kt/V summaries require patients dialyzed thrice weekly. Information regarding the determination of thrice-weekly dialysis is provided below.

Determination of thrice weekly dialysis

A patient-month was excluded from the hemodialysis Kt/V patient counts described above if the prescribed number of sessions reported in EQRS by the patient's 'assigned' facility indicated the patient was undergoing 'frequent' (≥ 4) or 'infrequent' (≤ 2) dialysis anytime during the reporting month. If information regarding the frequency of dialysis was not available for the reporting month in EQRS by the patient's 'assigned' facility, session information submitted by other dialysis facilities where the patient received treatment was considered.

If the dialysis frequency was not reported in EQRS for the reporting month, eligible hemodialysis Medicare claims submitted by the patient's 'assigned' facility during the reporting month were considered. A claim was considered eligible if it was for an adult (≥ 18 years old) HD patient with ESRD for more than 90 days as of the start of the claim. Any patient-month in which the patient received "frequent" or "infrequent" dialysis according to claims was excluded entirely (more details provided below).

If the prescribed dialysis information was not available for the patient during the reporting month in either data source (EQRS or Medicare claims), the patient-month was excluded from the denominator.

Calculating “frequent” and “infrequent” dialysis in Medicare dialysis claims

The number of dialysis sessions per week on a claim was calculated as a rate: $7 * (\# \text{ of HD sessions} / \# \text{ of days})$. This rate was only calculated for claims that covered at least seven days. A claim was identified as indicating “frequent” dialysis if any of the following criteria were met:

- (a) reported a Kt/V value of 8.88,
- (b) covered seven or more days and had a rate of four or more sessions/week, or
- (c) covered fewer than seven days and had four or more total sessions indicated

A claim was identified as indicating “infrequent” dialysis if it covered at least seven days and had a rate of two or fewer sessions/week. No short claims (less than 7 days) were considered as indicating “infrequent” dialysis.

Kt/V Categories for Adult HD Patients

(K-dialyzer clearance of urea; t-dialysis time; V-patient’s total body water)

Adult HD Kt/V summaries are calculated using EQRS as the primary data source. The last Kt/V collected (from any facility) during the reporting month for the patient was selected. If Kt/V was missing or out of range (Kt/V value greater than 5.0) in EQRS, then the Kt/V (based on value code ‘D5: Result of last Kt/V’) reported on the last eligible Medicare claim for the patient during the reporting month was selected when available.

A claim was considered eligible if it was from a HD patient who had ESRD for more than 90 days, was at least 18 years old, and the claim was neither a “frequent” dialysis claim nor an “infrequent” dialysis claim as described above. The last eligible claim with an in-range (less than or equal to 5.0) and not expired (in-center HD with Kt/V reported from a previous claim, or home HD with Kt/V reported from more than four months’ prior) Kt/V value reported was selected when there were multiple claims reported in a month. Patient-months were excluded if any claim submitted during the month for the patient identified the patient as undergoing ‘frequent’ or ‘infrequent’ dialysis anytime during the reporting month.

The Kt/V value for each patient-month was characterized into three mutually exclusive categories: missing (no Kt/V reported), in range (Kt/V less than or equal to 5.0), and out of range (Kt/V value greater than 5.0). The percentages of all patient-months with Kt/V values <1.2, and missing/out of range values are shown in for HD adequacy. Summaries for 2018-2021 are reported in Table 9 (rows 9k) of the FY 2023 DFR.

Weekly Kt/V Categories for Adult PD Patients

(K-dialyzer clearance of urea; t-dialysis time; V-patient’s total body water)

Adult PD Kt/V values are only required to be reported every four months for adult PD patients. Therefore, if Kt/V was missing for the reporting month, the most recent available value collected up to 3 months prior was selected when available. If all values in a 4-month look-back period were missing, then the PD Kt/V value was considered missing for that reporting month.

Summaries are calculated using EQRS as the primary data source. The last Kt/V collected (from any facility) during the reporting month for the patient was selected. If Kt/V was missing or out of range (Kt/V value greater than 8.5) in EQRS, then the Kt/V (based on value code 'D5: Result of last Kt/V') reported on the last eligible Medicare claim for the patient during the reporting month was selected when available.

A claim was considered eligible if it was from a PD patient who had ESRD for more than 90 days and was at least 18 years old. The last eligible claim with an in-range (less than or equal to 8.5) and not expired (Kt/V reported from more than four months' prior) Kt/V value was selected when there were multiple claims reported in a month.

The Kt/V value for each patient-month was characterized into three mutually exclusive categories: missing (no Kt/V reported), in range (Kt/V value less than or equal to 8.5), and out of range (Kt/V value greater than 8.5). The percentages of all patient-months with Kt/V values <1.7, and missing or out of range values are shown for PD adequacy. Summaries for 2018-2021 are reported in Table 9 (rows 9o) of the FY 2023 DFR.

Data limitations for 2020

Due to the lookback period for PD Kt/V, values were calculated only for October through December 2020.

IX. Nutrition

This section reports measures of nutrition separately for adult hemodialysis (HD) and peritoneal dialysis (PD) patients among patients reported in Section IV, respectively. This section of the table is based on information collected in EQRS.

Serum Albumin Categories Among HD Patients

Serum albumin was assessed among all eligible HD patient-months during the reporting period among HD patients reported in Section IV. When multiple values were submitted during the month for the patient (by any facility), the most recent value was selected. The highest value was selected if multiple values were submitted on the same day. The percentage all patient-months with serum albumin less than 4.0 g/dL is reported. Summaries for 2018-2021 are reported in Table 9 (row e) of the FY 2023 DFR.

Serum Albumin Categories Among PD patients

Serum albumin was assessed among all eligible PD patient-months during the reporting period among PD patients reported in Section IV. When multiple values were submitted during the month for the patient (by any facility), the most recent value was selected. The highest value was selected if multiple values were submitted on the same day. The

percentage of all patient-months with serum albumin less than 4.0 g/dL is reported. Summaries for 2018-2021 are reported in Table 9 (row r) of the FY 2023 DFR.

X. Influenza Vaccination

This section reports influenza vaccination summary statistics for all dialysis patients treated on December 31st of each year in the facility, based on vaccinations reported in EQRS. These include all HD, PD, and uncertain dialysis patients greater than six months of age as of the beginning of the flu season each year. Patients that did not receive a vaccination and ever reported “Medical Reason: Allergic or Adverse Reaction” or “Other Medical Reason” during the flu season were excluded.

The percentage of patients who had a vaccination reported in EQRS performed between August 1st and March 31st of the following year. Average values for the most recent full flu season are also reported among patients in the state, Network, and the U.S. We provide vaccination summaries from the full flu season (August 1st through March 31st of the following year). Summaries for 2018-2021 full and half (August 1st through December 31st) flu seasons are reported in Table 7 (row c) of the FY 2023 DFR.

XI. Mineral Metabolism

This section reports measures of mineral metabolism for adult dialysis patients based on information collected in EQRS.

Phosphorous Categories Among Adult Patients

Phosphorus summaries include all adult patient-months from Section IV (HD and PD) within the first 90 days of ESRD. Therefore, the patient-count reported in Section IV does not include all patients included in the phosphorous summaries. The percentage of all patient-months with in-range (0.1 mg/dL to 20 mg/dL) phosphorous values >7.0 mg/dL, and missing or out of range phosphorous values are reported. When multiple values were submitted during the month for the patient (by any facility), the most recent value was selected. The highest value was selected if multiple values were submitted on the same day. Summaries for 2018-2021 are reported in Table 10 (row d) of the FY 2023 DFR.

Calcium Uncorrected Categories Among Adult Patients

The percentage of all patient-months (HD and PD) for patients reported in Section IV with in-range (0.1 mg to 20 mg/dL) calcium uncorrected value greater than 10.2 mg/dL, and missing or out of range values are reported. When multiple values were submitted during the month for the patient (by any facility), the most recent value was selected. The highest value was selected if multiple values were submitted on the same day. Summaries for 2018-2021 are reported in Table 10 (row f) of the FY 2023 DFR.

Average Uncorrected Calcium > 10.2 mg/dL (1y)

The percentage of all eligible patient-months with a 3-month rolling average uncorrected serum or plasma calcium greater than 10.2 mg/dL or missing is reported in this row. This value is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period among eligible patients (HD and PD) reported in Section IV who are 18 years or older two months prior to the reporting month.

The percentage for a given month uses the average of the last reported uncorrected serum or plasma calcium value and the last reported values for the previous 2 months (if available). The acceptable range for calcium is 0.1 – 20 mg/dL. Values outside of this range are considered missing. For example, the percentage calculated for April would be based on the average of uncorrected serum calcium values submitted in April, March and/or February. Patients with missing values who meet the criteria above are included in the numerator. Summaries for 2018-2021 are reported in Table 10 (row g) of the FY 2023 DFR.

XII. Transplantation

For detailed explanation about the Standardized 1st Transplantation Ratio (row 1x) and the Age-Adjusted percentage of patients waitlisted (row 1z), please refer section VIII and IX on the Guide to the Dialysis Facility Reports for FY 2023, which can be found on the Methodology page of www.DialysisData.org.

The results of numerous studies have indicated that the recipients of renal transplants have better survival than comparable dialysis patients (Wolfe, 1999). The first step in the transplant process is getting placed on the transplant waitlist. This information was obtained from Organ Procurement and Transplantation Network (OPTN) / Scientific Registry of Transplant Recipients (SRTR) data.

Percentage of Patient-months on the Waitlist

This measure tracks the percentage of patients under age 75 at each dialysis facility who were on the kidney or kidney-pancreas transplant waitlist. For each month, a patient is included in the prevalent waitlist summary if they were indicated as receiving treatment at the facility on the last day of the calendar month according to the methods described in Section III. In addition, months indicating patients were admitted to a skilled nursing facility (SNF) according to the CMS long-term care minimum data set, patients who were admitted to a SNF previously according to the CMS Medical Evidence Form (questions 16u and 21), and/or active hospice patients reported on Medicare final action claims data were excluded. A patient may only be assigned to one facility each month may contribute up to 3 or 12 times per quarter or year, respectively.

The percentage of eligible patient-months on the kidney or kidney-pancreas transplant waiting list as of the last day of each calendar month during the reporting period and the percentage of eligible patient-months on the waitlist are reported in this section.

XIII. Nursing Home Patients

This section reports the number of all dialysis patients, as well as the percentage of nursing home patients among all dialysis patients in a facility. Nursing home patients are defined as the patients in CMS Long Term Care Minimum Data Set (MDS) at any time during the reporting period. The percentage of nursing home patients includes all patients receiving dialysis (any modality) at any time during the reporting period.

The number of dialysis patients treated on last day of the year/quarter, as well as the percent of these patients on receiving dialysis through the following modalities: In-center hemodialysis, Home hemodialysis, Continuous ambulatory peritoneal dialysis, Continuous cycling peritoneal dialysis and other are also reported. The 'Other' modality category includes other dialysis, uncertain modality, and patients not on dialysis but still temporarily assigned to the facility (discontinued dialysis, recovered renal function, and lost to follow-up). In addition, SMR and SHR among nursing home patients for the most recent two years of the DFR are reported in the section. See *Guide to the FY 2023 DFR* for SMR (Section VI) and SHR (Section VII) methodology.

XIV. COVID Tables (C1 and C2)

The COVID-19 pandemic continues to have a profound impact on the US healthcare system including ESRD providers and the high-risk dialysis population. To assist dialysis surveyors and other stakeholders in investigating the impact of COVID-19, we have developed tables to report on COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2) in 2021 and 2022 Q1-. State, Network, and National averages for 2021 are included for comparison.

Population

Since the main source for COVID-19 diagnosis is Medicare Claims, we calculate the COVID-19 patient counts among Medicare dialysis patients. Medicare dialysis patients are defined as patients who received dialysis (any modality) and were Medicare eligible at any time during the reporting period including those within the first 90 days of ESRD (Item 1 in Table C1). Medicare NH dialysis patients are defined as Medicare dialysis patients who appeared in the CMS Long Term Care Minimum Data Set (MDS) at any time during the reporting period (Item 1 in Table C2).

Identifying COVID-19 patients

Throughout the COVID-19 pandemic, UM-KECC has been actively monitoring data indicators related to diagnosis and treatment of COVID-19 across all available and relevant data sources. Patients ever identified with COVID are defined as those patients who were diagnosed with COVID by the end of each quarter or quarters, regardless of whether the diagnosis occurred prior to or during the reporting period (Item 2). Patients first identified with COVID are defined as those patients who were newly diagnosed with COVID within the quarter (Item 3). The percentages of patients first or ever identified with COVID among Medicare dialysis patients are also reported.

Mortality and hospitalization counts

Death (Items 4 and 5) and hospitalization (Items 6 and 7) counts are calculated among all patients in Item 1 and patients ever identified with COVID in Item 2 during the reporting period. Deaths are obtained from multiple data sources including the Death Notification Form (CMS Form 2746), the Enrollment Database (EDB), and Medicare claims. Hospitalization is defined as having at least one day in a hospital from Medicare inpatient claims during the reporting period. A death or hospitalization in this category does not mean a patient died or was hospitalized from COVID. The percentages of deaths or hospitalizations of patients ever identified with COVID out of all deaths or hospitalizations are also reported.

XIII. Please Give Us Your Comments

We welcome questions or comments about this report's content, or any suggestions you might have for future reports of this type. Improvements in the content of future reports will depend on feedback from the nephrology community. Facility-specific comments may be submitted on the secure portion of www.Dialysisdata.org by authorized users only. General methodological questions may be submitted by anyone using the form available on the "Contact Us" tab on www.Dialysisdata.org.

References

- Agresti, A. *Categorical Data Analysis*, Second Edition, New York: John Wiley & Sons, Inc.; 2002
- Health, United States, 2015 *With Special Feature on Racial and Ethnic Health Disparities*. Centers for Disease Control and Prevention, Health and Human Services Dept., 99-102. <http://www.cdc.gov/nchs/hestats/contetns2015.htm#017>
- NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. National Kidney Foundation. *Am J Kidney Dis.* 1997 Sep; 30 (3 Suppl 2): S15-66.
- NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. *Am J Kidney Dis.* 1997 Oct;30(4 Suppl 3):S192-240.
- NKF-KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. *Am J Kidney Dis.* 2001 Jan; 37 (1 Suppl 1): S7-S64.
- NKF-KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. *Am J Kidney Dis.* 2001 Jan;37(1 Suppl 1): S182-238.
- NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2006. *Am J Kidney Dis.* Volume 48, Supplement S1 (July 2006) *pages S2-S90*
- NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2006. *Am J Kidney Dis.* Volume 47, Supplement S3, Pages 146-146 (May 2006):